State AR
Clinical Trials in Arkansas
Arkansas is home to a significant concentration of clinical research activity, with academic medical centers, community hospitals, and specialized research clinics serving as active trial sites across a broad range of medical conditions. The studies listed here have at least one enrolled site in Arkansas and represent Phase 1 through Phase 4 research sponsored by NIH, pharmaceutical companies, device manufacturers, and independent investigators.
Right now ClinicalMetric tracks 102 actively recruiting studies with Arkansas sites out of 102 registered in total. The busiest research areas in Arkansas are Atopic Dermatitis, B Acute Lymphoblastic Leukemia, Schizophrenia. Leading sponsors running trials in the state include National Cancer Institute (NCI), Pfizer, University of Arkansas. By stage, Arkansas trials break down as Phase 1 (9), Phase 2 (30), Phase 3 (39), Phase 4 (2).
All trial data is sourced directly from ClinicalTrials.gov and updated daily. Recruiting status, eligibility criteria, enrollment targets, and contact information are included for each study. Patients and caregivers should review the full eligibility criteria on each trial listing — or consult their treating physician — before contacting a study site.
Top Conditions in Arkansas
Atopic Dermatitis (4)B Acute Lymphoblastic Leukemia (3)Schizophrenia (3)Malignant Solid Neoplasm (2)Atrial Fibrillation (2)Non-muscle Invasive Bladder Cancer With Carcinoma in Situ (2)Clear Cell Renal Cell Carcinoma (2)Ulcerative Colitis (2)Heart Failure (2)Heart Diseases (2)Cardiovascular Diseases (2)Non-Small Cell Lung Cancer (2)
Frequently Asked Questions — Clinical Trials in Arkansas
How many clinical trials are currently recruiting in Arkansas?
ClinicalMetric currently tracks 102 actively recruiting clinical trials with at least one location in Arkansas. The total number of registered studies—including active but not currently enrolling trials—is 102. Trial availability is updated daily from ClinicalTrials.gov, and new studies open enrollment regularly throughout the year.
What types of clinical trials are available in Arkansas?
Arkansas hosts clinical trials across a broad range of medical conditions, including Atopic Dermatitis, B Acute Lymphoblastic Leukemia, Schizophrenia, and many others. Trials range from Phase 1 early-safety studies to Phase 4 post-approval surveillance, as well as observational and behavioral research. Academic medical centers, community hospitals, and specialized research clinics throughout Arkansas serve as trial sites for studies sponsored by NIH, pharmaceutical companies, and independent investigators.
How do I join a clinical trial near me in Arkansas?
To join a clinical trial in Arkansas, browse the recruiting studies listed on this page, review the eligibility criteria for each trial, and contact the study site directly. Your primary care physician or specialist can also refer you to clinical trials relevant to your diagnosis. Many academic medical centers in Arkansas maintain dedicated clinical trials offices that can match you with appropriate studies based on your medical profile and diagnosis.
Recruiting Trials in Arkansas
NCT06524882 Phase 3
Recruiting
Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age
Condition
Amblyopia
Enrollment
252 pts
Location
United States
Sponsor
Jaeb Center for Health Researc
NCT07113522 Phase 2
Recruiting
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
Condition
Inflammatory Bowel Disease (IBD)
Enrollment
140 pts
Location
United States, Canada, Georgia
Sponsor
Mirador Therapeutics, Inc.
NCT06313502 Phase 1
Recruiting
High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders
Condition
Plasma Cell Disorder
Enrollment
18 pts
Location
United States
Sponsor
University of Arkansas
NCT07061977 Phase 3
Recruiting
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemor...
Condition
Locally Advanced Cervical Adenocarcinoma
Enrollment
336 pts
Location
United States, Puerto Rico
Sponsor
National Cancer Institute (NCI
NCT06568939 Phase 2
Recruiting
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzuma...
Condition
Non-Small Cell Lung Cancer
Enrollment
150 pts
Location
United States, Brazil, China
Sponsor
AbbVie
NCT04726241 Phase 1, Phase 2
Recruiting
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marr...
Condition
Acute Lymphoblastic Leukemia
Enrollment
960 pts
Location
United States, Australia, Canada
Sponsor
PedAL BCU, LLC
NCT06958328 Phase 3
Recruiting
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Condition
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma
Enrollment
356 pts
Location
United States, Canada
Sponsor
NRG Oncology
NCT06598943 Phase 2
Recruiting
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Seve...
Condition
Ulcerative Colitis
Enrollment
143 pts
Location
United States, Argentina, Belgium
Sponsor
Eli Lilly and Company
NCT06980948 Phase 1, Phase 2
Recruiting
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Ne...
Condition
Chronic Neuropathic Pain
Enrollment
27 pts
Location
United States
Sponsor
Sangamo Therapeutics
NCT05156398 Phase 3
Recruiting
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migrai...
Condition
Migraine
Enrollment
640 pts
Location
United States, Canada, France
Sponsor
Pfizer
NCT07136012 Phase 3
Recruiting
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a)...
Condition
Cardiovascular Disease
Enrollment
11,000 pts
Location
United States, Australia, Canada
Sponsor
Amgen
NCT07686263 Phase 3
Recruiting
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
Condition
Schizophrenia
Enrollment
472 pts
Location
United States, Argentina, Bulgaria
Sponsor
Karuna Therapeutics, Inc., a B
NCT05812807 Phase 3
Recruiting
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who H...
Condition
Anatomic Stage II Breast Cancer AJCC v8
Enrollment
1,295 pts
Location
United States, Canada, Puerto Rico
Sponsor
Alliance for Clinical Trials i
NCT06747884 N/A
Recruiting
Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extensio...
Condition
Congenital Myotonic Dystrophy
Enrollment
200 pts
Location
United States, Brazil
Sponsor
Virginia Commonwealth Universi
NCT06873945 Phase 3
Recruiting
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alop...
Condition
Alopecia Areata
Enrollment
1,330 pts
Location
United States, Canada, China
Sponsor
Pfizer
NCT06430801 Phase 3
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Partici...
Condition
Crohn's Disease
Enrollment
1,200 pts
Location
United States, Australia, Austria
Sponsor
Merck Sharp & Dohme LLC
NCT07527299 N/A
Recruiting
A Study of VARIPULSE Catheter in Participants With Persistent Atrial Fibrillatio...
Condition
Atrial Fibrillation
Enrollment
1,070 pts
Location
United States
Sponsor
Biosense Webster, Inc.
NCT05059444 N/A
Recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Condition
Bladder Carcinoma
Enrollment
2,285 pts
Location
United States, France, Germany
Sponsor
Guardant Health, Inc.
NCT05848687 Phase 1, Phase 2
Recruiting
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Condition
Lymphoblastic Leukemia
Enrollment
90 pts
Location
United States, Canada
Sponsor
Tanja Andrea Gruber
NCT04088071 N/A
Recruiting
Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias
Condition
Paroxysmal Atrial Fibrillation
Enrollment
20,000 pts
Location
United States, Canada
Sponsor
Heart Rhythm Clinical and Rese
NCT07601074 Phase 2
Recruiting
A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Hu...
Condition
Human Papilloma Virus (HPV)
Enrollment
118 pts
Location
United States
Sponsor
Daré Bioscience, Inc.
NCT07766655 Phase 3
Recruiting
Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)
Condition
Smoking Cessation
Enrollment
705 pts
Location
United States
Sponsor
Axsome Therapeutics, Inc.
NCT04871542 N/A
Recruiting
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Condition
Malignant Solid Neoplasm
Enrollment
2,062 pts
Location
United States, Chile, Guam
Sponsor
SWOG Cancer Research Network
NCT06124157 Phase 2
Recruiting
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatme...
Condition
B Acute Lymphoblastic Leukemia
Enrollment
222 pts
Location
United States, Australia, Canada
Sponsor
National Cancer Institute (NCI
NCT07221877 Phase 4
Recruiting
A Study to Evaluate the Effect of KarXT on Urological Safety
Condition
Schizophrenia
Enrollment
60 pts
Location
United States
Sponsor
Bristol-Myers Squibb
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology